

RECORDATI: 2019 CORPORATE EVENTS' CALENDAR

Milan, 28 January 2019 – Recordati S.p.A. hereby communicates the calendar of corporate events for 2019:

- 5 February** Ordinary Shareholders' Meeting to appoint the new Board of Directors.
- 11 February** Board of Directors' meeting to approve the 2018 preliminary consolidated results.
- 28 February** Board of Directors' meeting to approve the 2018 consolidated financial statements and the draft of Recordati S.p.A.'s 2018 financial statements as well as the 2018 disclosure of consolidated non financial information.
- 11 April** Annual Shareholders' Meeting to approve Recordati S.p.A.'s 2018 financial statements.
- 8 May** Board of Directors' meeting to approve the 2019 first quarter results¹ as well as to approve the 2019-2021 business plan.
- 9 May** *Meeting with the financial community and specialized press.*
- 30 July** Board of Directors' meeting to approve the 2019 half-yearly report.
- 31 October** Board of Directors' meeting to approve the 2019 first nine months' results².

Recordati S.p.A. announces that the payment of the balance of the 2018 financial year dividend is planned for 25 April 2019, on each outstanding share at 23 April 2019 (ex-dividend date) and record date 24 April 2019, while payment of the interim dividend for the 2019 financial year is planned for 20 November 2019, on each outstanding share at 18 November 2019 (ex-dividend date) and record date 19 November 2019.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar will be promptly notified to the market.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative

¹ Please be reminded that, as a result of the fact that Italian Legislative Decree n. 25/2016 enacting Directive 2013/50/EU eliminated the mandatory requirement to disclose the interim financial report, Recordati S.p.A. has decided, pursuant to art.82-ter of Issuers Regulation, to continue disclosing the quarterly reports, on a voluntary basis and until any different decision is taken in this respect, with comparable form and content to those of the previous financial years.

² Please see note n.1 above.

pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.